Introduction
GP53,633 (2-tert. butyl-4(5)phenyl-5(4)-(3 pyridyl)-imidazole; Ciba-Geigy) is a new nonsteroidal anti-inflammatory drug (NSAID) which has been shown to have analgesic and antiinflammatory activities in animals and, like other NSAID's, acts as an inhibitor of prostaglandin synthesis in various test systems. GP53,633 is an analogue of phenylbutazone but is a base rather than an acid [1] . Both GP53,633 and phenyl-butazone are hydroxylated at the same position on the phenyl ring producing CGP8716 and oxyphenbutazone respectively. The structure of GP53,633 and its major metabolite is shown in Fig. 1 . This paper describes the pharmacokinetics and clinical effects of GP53,633 and its known metabolite CGP8716 in 6 patients with rheumatoid arthritis.
Materials and methods
Six patients with rheumatoid arthritis according to the American Rheumatism Association criteria [2] were studied. Three of the patients were female. The mean age of the patients was 54 years (range 42 to 65 years) with a mean duration of rheumatoid arthritis of 3 years (range 1.5 to 5 years). None of the patients were taking gold, openicillamine or immunosuppressive agents. The study was approved by the Clinical Research and Ethics Committee of the Institution. After meeting selection criteria for the trial all non-steroidal anti-inflammatory-analgesic medication was ceased and the patient seen again 3 days later having been fasting for the previous 10 hours. At the commencement of the study all patients fulfilled at least 3 of 4 criteria for active disease (6 or more joints painful or tender on movement, 3 or more swollen joints, morning stiffness of 45 minutes or more and an ESR of 28 mm or more). The first dose of GP53,633 (200 mg) was taken with 100 ml of water and blood collected prior to and at 20, 40, 60 and 90 minutes, 2, 4, 6 and 8 hours after the doses. Urine was collected prior to and in periods from 0 to 2, 2 to 4, 4 to 8 and 8 to 24 hours after administration. After blood collection and centrifugation, the plasma was stored at -20~ until analysed. Patients continued to take 200 mg of GP53,633 3 times a day for the duration of the study (14 days). Clinical assessments were made at days 0, 7 and 14. Plasma collection over a dosing interval (8 hours) was made following the last dose of GP53,633 taken after a 10 hour fast on the morning of day 15.
All clinical assessments were made at the same time of day, by the same measurement technician. The following clinical measurements were made; duration of morning stiffness (hours), articular index according to the method of RIrcmE et al. [3] , pain assessment at rest, on movement and at night measured on a 4 point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). At each visit the patient assessed the state of the arthritis on a scale of 1 to 5 (1 = very good, 5 = very poor), and on the final day the physician completed an overall evaluation of therapeutic effect 0 = none, 1 = poor, 2 = good, or satisfactory effect and 3 = excellent or best possible effect. Adverse effects were checked at each visit by asking the patient if they were upset by the medication in any way, and if so, in what way. Laboratory tests of full blood count, prothrombin time, liver function tests, glucose and urea electrolytes together with urinalysis were performed on days 0, 7 and 14.
The determination of GP53,633 and its major metabolite (CGP8716) in plasma and urine was carried out by high performance liquid chromatography. The method was performed using a Waters 6,000A Solvent Delivery System, Waters U6K Universal injector and an Altex model 110 fixed wave-length detector operating at 254 nm. The instrument was fitted with a 30 cmx 3.9 mm (I.D.) reverse phase Bondapak C-18 column (Waters Associates). Separation was achieved with a solvent system of 10 mM citrate buffer, pH 3 : acetonitrile (3 : 1) at a flow rate of 2 ml/min. GP53,633, its major metabolite CGP8716 and internal standard (GP55,572) were supplied by Ciba-Geigy Ltd. (Australia). One ml of plasma was placed into a 10 ml capacity inert lined screwcap culture tube along with 0.1 ml of the internal standard (GP55,572) in methanol. Diethyl ether 5 ml was added and the sample extracted using a vortex mixer for 2 minutes. The organic and aqueous phases are separated by centrifugation for 5 minutes and the aqueous phase frozen in a dry ice-acetone bath. The upper organic phase was poured into a conical tip glass tube and ether was evaporated at room temperature. Mobile phase (0.25 ml) was added to each tube, vortexed for 1 minute and centrifuged and 70/tl of sample injected into the chromatography system. Calibration standards of GP53,633 and CGP8716 were prepared by evaporating the appropriate volume of methanolic stock solution and re-constituting the residue in drug free plasma and processed in a similar fashion. Chromatograms showing sharp symmetrical peaks with retention times of 4.75, 8.6 and 12.0 minutes were obtained for CGP8716, GP53,633 and the internal standard respectively. Linear calibration curves were obtained by using plots of peak height ratios of each compound vs their known concentration in the range of 0.05-1.5 mg/1. Intra-assay co-effieients of variation were 1.2% and 5.9% for GP53,633 and CGP8716 respectively. The recoveries of GP53,633 and CGP8716 from plasma were found to be 95 + 4% and 92 + 5% respectively in the concentration range 0.05 to 1.5 mg/i using diethyl ether as the extraction solvent.
Pharmaeokinctic calculations
The elimination constant (ke,) was calculated by linear regression analysis of the terminal elimination phase of the plasma concentration time curve.
Apparent clearances on day 1 and day 14 were calculated as follows: Results Table 1 shows the pharmacokinetic data for GP53,633 on day 0 and day 14. Absorption was rapid with peak plasma levels occurring approximately 1 hour after ingestion. The elimination half-life was approximately 2 hours. There was no significant difference between the pharmacokinetic parameters on day 0 and after 14 days of treatment with 600 mg GP53,633 dally. Similarly there were no differences between days 0 and 14 for any of the parameters measured for the metabolite CGP8716 (Table 2) .
Small amounts (less than 5%) of the dose were recovered in urine as GP53,633 and CGP8716. Table 3 summarizes the clinical measures of inflammation at the beginning and end of the 14 day treatment period. Though there is a consistent trend towards reduction in disease activity in all measures except duration of morning stiff- Values given are mean and standard deviation of mean (n = 6). Parameters shown are the same as in Table i . ness, for none of these parameters was statistical significance reached.
Discussion
Many new non-steroidal anti-inflammatory drugs have been produced over the last few years. Some are very like existing agents but others have subtle differences in their effects on cellular or humoral aspects of inflammation [4] . A number of clinical studies have demonstrated marked individual variation in response to non-steroidal anti-inflammatory drugs [5] [6] [7] and as the perfect agent has not been produced to treat rheumatoid arthritis it would seem important to continue to investigate new compounds.
GP53,633 is interesting in that it is a base rather than an acid in contrast to most other NSAID. Recent studies have shown that GP53,633 is a highly protein bound drug like other acidic NSAID [1] . Binding studies in the present 6 patients using equilibrium dialysis following the method described earlier [ 1 ] showed the free fraction of GP53,633 to be 2.6% with a range 2.0-3.5% representing 96.5 to 98% protein bound in the plasma.
The pharmacokinetic data showed rapid absorption of GP53,633 with peak plasma levels being achieved approximately 1 hour after ingestion. There was no significant difference between the pharmacokinetic parameters of GP53,633 and its known metabolite CGP8716 between the initial 200 mg dose and the dose taken after 14 days of treatment with 600 mg daily. There is thus no evidence that metabolism or elimination of the drug is altered in any way during a 2 week dosing period. The urinary excretion of GP53,633 and its known metabolite CGP8716 accounted for up to 5% of the dose suggesting that other metabolites such as the glucuronide conjugate may be important metabolites of this drug. Alternative, this drug may be excreted by other routes. Though clinical improvement did not reach statistical significance (p > 0.1) it was seen in all parameters except the duration of morning stiffness. Night pain for example occurred in 5 of 6 patients at the beginning of the study but in only one of the 6 patients at the end of 14 days treatment. Patient assessment of therapeutic effect was high (2.8 + 1.7) and no side effects were noted during the studies. The number of patients studied was small (n = 6) and it is possible that by increasing the numbers, statistically significant changes in clinical parameters would be achieved. This study was terminated after only 6 patients had been entered as the drug was withdrawn from human investigation pending further evaluation of animal toxicity data.
No significant changes were seen in routine full blood counts, prothrombin index, liver function test or urea and electrolytes performed prior to the study and at the end of 7 and 14 days. In summary GP53,633 taken at a dose of 600 mg daily for 14 days did not produce any adverse reactions and tended to reduce most of the clinical parameters of disease activity in 6 patients with active rheumatoid arthritis.
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